Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6118688 | 0.88 | TDP1 (0.44) | TDP1NOS1ALDH1A1L3MBTL1MITF | |
| SCHEMBL476964 | 0.84 | CNR1 (0.46) | TDP1NOS1ALDH1A1LMNAHTT | |
| SCHEMBL6117729 | 0.84 | TDP1 (0.43) | TDP1NOS1ALDH1A1L3MBTL1MITF | |
| SCHEMBL11611635 | 0.84 | GAA (0.51) | TDP1NOS1ALDH1A1MEN1KMT2A | |
| SCHEMBL30861009 | 0.83 | TDP1 (0.46) | TDP1NOS1ALDH1A1MEN1KMT2A | |
| SCHEMBL27228011 | 0.83 | TDP1 (0.46) | TDP1NOS1ALDH1A1MEN1KMT2A | |
| SCHEMBL27227825 | 0.82 | LMNA (0.43) | TDP1NOS1ALDH1A1MEN1KMT2A | |
| SCHEMBL4554503 | 0.82 | TDP1 (0.44) | TDP1NOS1ALDH1A1L3MBTL1MITF | |
| SCHEMBL27227989 | 0.82 | TDP1 (0.44) | TDP1NOS1ALDH1A1MEN1KMT2A | |
| SCHEMBL6123468 | 0.81 | TDP1 (0.41) | TDP1NOS1ALDH1A1L3MBTL1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024099269-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF | 华东师范大学 | 2024-05-16 | — | — | WO | disclosed |
| CN-118026880-A | Aryl amide compound, pharmaceutical composition containing same and application thereof | 华东师范大学 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-2799431-B1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2018-01-24 | — | — | EP | disclosed |
| EP-2799431-B1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2018-01-24 | — | — | EP | disclosed |
| US-9388192-B2 | Benzimidazole derivatives as Kinase Inhibitors | SELVITA S.A. (PL) | 2016-07-12 | — | — | US | disclosed |
| CN-104024226-B | Novel nicotinamide derivative or salt thereof | FUJIFILM CORP. (JP) | 2016-06-01 | — | — | CN | disclosed |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | Ryvu Therapeutics S.A. (PL) | 2015-11-26 | — | — | US | disclosed |
| US-9051310-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| CN-101917999-A | Modulation of protein trafficking | FOLDRX PHARMACEUTICALS INC | 2010-12-15 | — | — | CN | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2217239-A2 | MODULATION OF PROTEIN TRAFFICKING | Foldrx Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-101460161-A | Inhibition of alpha-synuclein toxicity | FOLDRX PHARMACEUTICALS INC (US) | 2009-06-17 | — | — | CN | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2007373-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | Foldrx Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, PINK1 | TDP1 356/4885NOS1 2907/4885ALDH1A1 2199/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | TDP1 608/4885NOS1 4272/4885ALDH1A1 4623/4885 |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | PIM1, PIM3, PIM2 | TDP1 455/4885NOS1 1488/4885ALDH1A1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.